{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:09:04Z","timestamp":1790780944769,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Leadership Fellowship","award":["1195830"],"award-info":[{"award-number":["1195830"]}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["APP1176426"],"award-info":[{"award-number":["APP1176426"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian National Health and Medical Research Council","award":["GNT1200254"],"award-info":[{"award-number":["GNT1200254"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,10,14]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Progressive supranuclear palsy (PSP) is a neurodegenerative disorder for which there are currently no disease-modifying therapies. The neuropathology of PSP is associated with the accumulation of hyperphosphorylated tau in the brain. We have previously shown that protein phosphatase 2 activity in the brain is upregulated by sodium selenate, which enhances dephosphorylation. Therefore, the objective of this study is to evaluate the efficacy and safety of sodium selenate as a disease-modifying therapy for PSP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This will be a multi-site, phase 2b, double-blind, placebo-controlled trial of sodium selenate. 70 patients will be recruited at six Australian academic hospitals and research institutes. Following the confirmation of eligibility at screening, participants will be randomised (1:1) to receive 52 weeks of active treatment (sodium selenate; 15\u2009mg three times a day) or matching placebo. Regular safety and efficacy visits will be completed throughout the study period. The primary study outcome is change in an MRI volume composite (frontal lobe+midbrain\u20133rd ventricle) over the treatment period. Analysis will be with a general linear model (GLM) with the MRI composite at 52 weeks as the dependent variable, treatment group as an independent variable and baseline MRI composite as a covariate. Secondary outcomes are change in PSP rating scale, clinical global impression of change (clinician) and change in midbrain mean diffusivity. These outcomes will also be analysed with a GLM as above, with the corresponding baseline measure entered as a covariate. Secondary safety and tolerability outcomes are frequency of serious adverse events, frequency of down-titration occurrences and frequency of study discontinuation. Additional, as yet unplanned, exploratory outcomes will include analyses of other imaging, cognitive and biospecimen measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the Alfred Health Ethics Committee (594\/20). Each participant or their legally authorised representative and their study partner will provide written informed consent at trial commencement. The results of the study will be presented at national and international conferences and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry (ACTRN12620001254987).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-055019","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:41:35Z","timestamp":1639654895000},"page":"e055019","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-0907","authenticated-orcid":false,"given":"Lucy","family":"Vivash","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L","family":"Bertram","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B","family":"Malpas","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Marotta","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H","family":"Harding","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kolbe","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Fielding","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Clough","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J G","family":"Lewis","sequence":"additional","affiliation":[{"name":"ForeFront Parkinson\u2019s Disease Research Clinic, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tisch","sequence":"additional","affiliation":[{"name":"Department of Neurology, St Vincent\"s Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia"},{"name":"Department of Neurology, Royal Brisbane & Women\"s Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kimber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darby","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia"},{"name":"Eastern Cognitive Disorders Clinic, Box Hill Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Churilov","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Radiology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Hovens","sequence":"additional","affiliation":[{"name":"Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Velakoulis","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Royal Melbourne Hospital, Parkville, Victoria, Australia"},{"name":"Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"2025121511265080000_11.12.e055019.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04137-9"},{"key":"2025121511265080000_11.12.e055019.2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn065"},{"key":"2025121511265080000_11.12.e055019.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30489-0"},{"key":"2025121511265080000_11.12.e055019.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn291"},{"key":"2025121511265080000_11.12.e055019.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70042-0"},{"key":"2025121511265080000_11.12.e055019.6","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1046\/j.1471-4159.1995.65062804.x","article-title":"Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase","volume":"65","author":"Goedert","year":"1995","journal-title":"J Neurochem"},{"key":"2025121511265080000_11.12.e055019.7","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/1.1.103"},{"key":"2025121511265080000_11.12.e055019.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.6474172"},{"key":"2025121511265080000_11.12.e055019.9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.8.5535"},{"key":"2025121511265080000_11.12.e055019.10","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000092859.16817.8e"},{"key":"2025121511265080000_11.12.e055019.11","first-page":"369","article-title":"Sodium selenate treatment mitigates reduction of bone volume following traumatic brain injury in rats","volume":"16","author":"Brady","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2025121511265080000_11.12.e055019.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605798"},{"key":"2025121511265080000_11.12.e055019.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.04.020"},{"key":"2025121511265080000_11.12.e055019.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.09.008"},{"key":"2025121511265080000_11.12.e055019.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.12.005"},{"key":"2025121511265080000_11.12.e055019.16","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww116"},{"key":"2025121511265080000_11.12.e055019.17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-160544","article-title":"A phase IIa randomized control trial of VEL015 (Sodium Selenate) in mild-moderate Alzheimer\"s disease","volume":"54","author":"Malpas","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2025121511265080000_11.12.e055019.18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv053"},{"key":"2025121511265080000_11.12.e055019.19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2016.05.001","article-title":"Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes","volume":"108","author":"Tan","year":"2016","journal-title":"Neuropharmacology"},{"key":"2025121511265080000_11.12.e055019.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.7058341"},{"key":"2025121511265080000_11.12.e055019.21","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-013-8601-9"},{"key":"2025121511265080000_11.12.e055019.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009038107"},{"key":"2025121511265080000_11.12.e055019.23","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0662-z"},{"key":"2025121511265080000_11.12.e055019.24","doi-asserted-by":"crossref","unstructured":"Vivash L , Malpas C , Hovens A , et al . Sodium selenate as a disease modifying treatment for mild-moderate Alzheimer\u2019s Disease: an open label extension study. BMJ Neurology Open;In press.doi:10.1136\/bmjopen-2020-040100","DOI":"10.1136\/bmjopen-2020-040100"},{"key":"2025121511265080000_11.12.e055019.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306948"},{"key":"2025121511265080000_11.12.e055019.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040100","article-title":"A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia","volume":"10","author":"Vivash","year":"2020","journal-title":"BMJ Open"},{"key":"2025121511265080000_11.12.e055019.27","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987"},{"key":"2025121511265080000_11.12.e055019.28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/mds.26973","article-title":"Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"2025121511265080000_11.12.e055019.29","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032"},{"key":"2025121511265080000_11.12.e055019.30","doi-asserted-by":"crossref","unstructured":"Guy W . Clinical Global Impressions. In: ECDEU assessment manual for psychopharmacology. Rockville MD: US Department of Health, Education and Welfare, 1976: 218\u201322.","DOI":"10.1037\/e591322011-001"},{"key":"2025121511265080000_11.12.e055019.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6177(03)00039-8"},{"key":"2025121511265080000_11.12.e055019.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1621"},{"key":"2025121511265080000_11.12.e055019.33","unstructured":"Benton AL , Hamsher KdeS . Multilingual aphasia examination: Mnaul of instruction. Iowa City: University of Iowa, 1976."},{"key":"2025121511265080000_11.12.e055019.34","doi-asserted-by":"crossref","unstructured":"Wechsler D . Wechsler adult intelligence scale. Vol. 22. Fourth Edition (WAIS\u2013IV). San Antonio, TX: NCS Pearson, 2008.","DOI":"10.1037\/t15169-000"},{"key":"2025121511265080000_11.12.e055019.35","unstructured":"Spreen O , Strauss E . A compendium of neuropsychological tests: Administration, norms and commentary. 2 ed. New York: Oxford University Press, 1998."},{"key":"2025121511265080000_11.12.e055019.36","unstructured":"Burgess PaS. T . Hayling and Brixton tests. Pearson, 1997."},{"key":"2025121511265080000_11.12.e055019.37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182872ded"},{"key":"2025121511265080000_11.12.e055019.38","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121511265080000_11.12.e055019.39","first-page":"906","article-title":"Development of the behavior rating inventory of executive Function-Adult version","volume":"20","author":"Roth","year":"2005","journal-title":"Arch Clin Neuropsychol"},{"key":"2025121511265080000_11.12.e055019.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.10.011"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-055019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:27:00Z","timestamp":1765826820000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-055019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,16]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjopen-2021-055019"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-055019","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}